Question

1 Approved Answer

Posted on Sep 20, 2024

1) Consider the following three firms in the Turkish pharmaceutical industry. a) Interpret the below financial statements with respect to firm strategy and positioning b)

1) Consider the following three firms in the Turkish pharmaceutical industry. a) Interpret the below financial statements with respect to firm strategy and positioning b) Calculate relevant financial performance metrics to highlight and demonstrate the differences in these firms' supply chain structures and approach. Nobel Las Eczacibaalias Deva Holding 46681 621734 125,071 10 851 46,048 850 385 672.782 233,627 88,567 4.442 1.927 1,001345 277,046 482,586 430,763 46,275 4,601 1,241,271 3793 87586 325 846 66 627 23,902 R480 0 516334 1.366, 719 3,358 248 373 351.340 102,914 1.667 13.101 9349 3,836,992 4,838,337 0 503 183 299 159 34,135 13.959 27,795 878,231 2,119,502 277 267 127,124 72.842 3,536 9509 7824 232,198 216.709 131.722 8,722 4.495 BALANCE SHEET CURRENT ASSETS Cash and Cash Equivalents Accounts Receivable Inventories Prepaid Expenses Other Current Assets Total Current Assets NON-CURRENT ASSETS Financial Investments Other Receivables Property Plant and Equipment Intangible Assets and Goodwill Prepaid Expenses Deferred Tax Asset Other Non-Current Assets Total Non-Current Assets Total Assets CURRENT LIABILITIES Current Borrowings Current Portion of Non-Current Borrowings Accounts Payable Employee Benefit Obligations Other Payables Deferred Income Other Than Contract Liabilities Current Tax Liabilities. Current Current Provisions Other Current Liabilities Total Current Liabilities NON-CURRENT LIABILITIES Long Term Borrowings vables Non-Current Provisions Deferred Tax Liabilities Total Non-Current abilities Total Liabilities Total Shareholders' Equity STATEMENT OF INCOME Sales Revenue Cost of Sales GROSS PROFIT General Administrative Expenses Marketing Expenses Research and Development Expense Other Income from Operating Activities Other Expenses from Operating Activities OPERATING INCOME Investment Activity Income Investment Activity Expenses Interest Income Interest Expense EARNINGS BEFORE TAX Tax Expense/Income Deferred Tax Expenses Income PROFIT (LOSS) B0,050 0 231 315 1.764 8,522 603 13357 4,786 18,157 358,554 3,033 2352 8 501 4,697 513,652 526 67,612 7.458 670,475 269.477 92073 25.569 20661 407780 921.432 445 287 17 764 19,498 4.118 161.145 202.525 561 079 4,277,258 352,713 37 666 27806 0 418,185 1,088 660 1030842 1,019.641 -386 435 633 206 -77.137 -332665 -25,824 97 194 -35,485 259 289 5,954 -7239 16 501 877,076 -561.262 315814 -63.766 -126 421 0 188,078 -88,799 224,906 113610 -72.290 4346 7.455 193117 -38,551 8162 162.728 1,373,983 -654824 719 159 -101.692 -178,857 -39,388 52,018 -24.552 426,688 2.299 -131 0 -148161 280.695 -1.946 7.267 286 016 170,870 -16 656 0 154,214 1) Consider the following three firms in the Turkish pharmaceutical industry. a) Interpret the below financial statements with respect to firm strategy and positioning b) Calculate relevant financial performance metrics to highlight and demonstrate the differences in these firms' supply chain structures and approach. Nobel Las Eczacibaalias Deva Holding 46681 621734 125,071 10 851 46,048 850 385 672.782 233,627 88,567 4.442 1.927 1,001345 277,046 482,586 430,763 46,275 4,601 1,241,271 3793 87586 325 846 66 627 23,902 R480 0 516334 1.366, 719 3,358 248 373 351.340 102,914 1.667 13.101 9349 3,836,992 4,838,337 0 503 183 299 159 34,135 13.959 27,795 878,231 2,119,502 277 267 127,124 72.842 3,536 9509 7824 232,198 216.709 131.722 8,722 4.495 BALANCE SHEET CURRENT ASSETS Cash and Cash Equivalents Accounts Receivable Inventories Prepaid Expenses Other Current Assets Total Current Assets NON-CURRENT ASSETS Financial Investments Other Receivables Property Plant and Equipment Intangible Assets and Goodwill Prepaid Expenses Deferred Tax Asset Other Non-Current Assets Total Non-Current Assets Total Assets CURRENT LIABILITIES Current Borrowings Current Portion of Non-Current Borrowings Accounts Payable Employee Benefit Obligations Other Payables Deferred Income Other Than Contract Liabilities Current Tax Liabilities. Current Current Provisions Other Current Liabilities Total Current Liabilities NON-CURRENT LIABILITIES Long Term Borrowings vables Non-Current Provisions Deferred Tax Liabilities Total Non-Current abilities Total Liabilities Total Shareholders' Equity STATEMENT OF INCOME Sales Revenue Cost of Sales GROSS PROFIT General Administrative Expenses Marketing Expenses Research and Development Expense Other Income from Operating Activities Other Expenses from Operating Activities OPERATING INCOME Investment Activity Income Investment Activity Expenses Interest Income Interest Expense EARNINGS BEFORE TAX Tax Expense/Income Deferred Tax Expenses Income PROFIT (LOSS) B0,050 0 231 315 1.764 8,522 603 13357 4,786 18,157 358,554 3,033 2352 8 501 4,697 513,652 526 67,612 7.458 670,475 269.477 92073 25.569 20661 407780 921.432 445 287 17 764 19,498 4.118 161.145 202.525 561 079 4,277,258 352,713 37 666 27806 0 418,185 1,088 660 1030842 1,019.641 -386 435 633 206 -77.137 -332665 -25,824 97 194 -35,485 259 289 5,954 -7239 16 501 877,076 -561.262 315814 -63.766 -126 421 0 188,078 -88,799 224,906 113610 -72.290 4346 7.455 193117 -38,551 8162 162.728 1,373,983 -654824 719 159 -101.692 -178,857 -39,388 52,018 -24.552 426,688 2.299 -131 0 -148161 280.695 -1.946 7.267 286 016 170,870 -16 656 0 154,214